Treatment of light chain deposition disease with bortezomib and dexamethasone

被引：58

作者：

Kastritis, Efstathios ^{[1
]}

Migkou, Magdalini ^{[1
]}

Gavriatopoulou, Maria ^{[1
]}

Zirogiannis, Panos ^{[2
]}

Hadjikonstantinou, Valsamakis ^{[3
]}

Dimopoulos, Meletios A. ^{[1
]}

机构：

[1] Univ Athens, Dept Clin Therapeut, Alexandra Hosp, Sch Med, Athens 11528, Greece

[2] G Gennimatas Gen Hosp, Athens, Greece

[3] Evangelismos Med Ctr, Athens, Greece

来源：

HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | 2009年 / 94卷 / 02期

关键词：

renal failure; autologous transplantation; glomerulosclerosis; proteinuria; MULTIPLE-MYELOMA; HEAVY-CHAIN; RENAL-FAILURE; CHEMOTHERAPY; INHIBITOR; TARGET;

D O I：

10.3324/haematol.13548

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：300 / 302

页数：3

共 13 条

[1] Nonamyloidotic monoclonal immunoglobulin deposition disease - Light-chain, heavy-chain, and light- and heavy-chain deposition diseases [J].

Buxbaum, J ;

Gallo, G .

HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 1999, 13 (06) :1235-+

[2] Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study [J].

Chanan-Khan, Asher A. ;

Kaufman, Jonathan L. ;

Mehta, Jayesh ;

Richardson, Paul G. ;

Miller, Kena C. ;

Lonial, Sagar ;

Munshi, Nikhil C. ;

Schlossman, Robert ;

Tariman, Joseph ;

Singhal, Seema .

BLOOD, 2007, 109 (06) :2604-2606

[3] Proteasome blockade exerts an antifibrotic activity by coordinately down-regulating type I collagen and tissue inhibitor of metalloproteinase-1 and up-regulating metalloproteinase-1 production in human dermal fibroblasts [J].

Fineschi, S ;

Reith, W ;

Guerne, PA ;

Dayer, JM ;

Chizzolini, C .

FASEB JOURNAL, 2006, 20 (01) :562-+

[4] LONG-TERM FOLLOW-UP AND RESPONSE TO CHEMOTHERAPY IN PATIENTS WITH LIGHT-CHAIN DEPOSITION DISEASE [J].

HEILMAN, RL ;

VELOSA, JA ;

HOLLEY, KE ;

OFFORD, KP ;

KYLE, RA .

AMERICAN JOURNAL OF KIDNEY DISEASES, 1992, 20 (01) :34-41

[5] NF-κB as a therapeutic target in multiple myeloma [J].

Hideshima, T ;

Chauhan, D ;

Richardson, P ;

Mitsiades, C ;

Mitsiades, N ;

Hayashi, T ;

Munshi, N ;

Dang, L ;

Castro, A ;

Palombella, V ;

Adams, J ;

Anderson, KC .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (19) :16639-16647

[6] Treatment of light chain (AL) amyloidosis with the combination of bortezomib and dexamethasone [J].

Kastritis, Efstathios ;

Anagnostopoulos, Athanasios ;

Roussou, Maria ;

Toumanidis, Savvas ;

Pamboukas, Constantinos ;

Migkou, Magdalini ;

Tassidou, Anna ;

Xilouri, Irini ;

Delibasi, Sossana ;

Psimenou, Erasmia ;

Mellou, Sofia ;

Terpos, Evangelos ;

Nanas, John ;

Dimopoulos, Meletios A. .

HAEMATOLOGICA, 2007, 92 (10) :1351-1358

[7]

Keeling J, 2007, CONTRIB NEPHROL, V153, P116

[8] Long-term outcome of autologous stem cell transplantation in light chain deposition disease [J].

Lorenz, Elizabeth C. ;

Gertz, Morie A. ;

Fervenza, Fernando C. ;

Dispenzieri, Angela ;

Lacy, Martha Q. ;

Hayman, Suzanne R. ;

Gastineau, Dennis A. ;

Leung, Nelson .

NEPHROLOGY DIALYSIS TRANSPLANTATION, 2008, 23 (06) :2052-2057

[9] Reversal of acute renal failure by bortezomib-based chemotherapy in patients with multiple myeloma [J].

Ludwig, Heinz ;

Drach, Johannes ;

Graf, Helmut ;

Lang, Alois ;

Meran, Johannes Gobertus .

HAEMATOLOGICA, 2007, 92 (10) :1411-1414

[10] Light chain deposition disease with renal involvement: Clinical characteristics and prognostic factors [J].

Pozzi, C ;

D'Amico, M ;

Fogazzi, GB ;

Curioni, S ;

Ferrario, F ;

Pasquali, S ;

Quattrocchio, G ;

Rollino, C ;

Segagni, S ;

Locatelli, F .

AMERICAN JOURNAL OF KIDNEY DISEASES, 2003, 42 (06) :1154-1163

← 1 2 →